Novartis Announces Positive Results from Phase III PALLADIUM Study of Inhaled Combination QMF149 in Patients with Uncontrolled Asthma
Basel, September 30, 2019 – Novartis today announced that investigational, once-daily, fixed-dose inhaled QMF149 (indacaterol acetate and mometasone furoate or IND/MF) was superior to mometasone furoate (MF) in improving trough forced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 30, 2019 Category: Pharmaceuticals Source Type: clinical trials
Novartis Announces Positive Results from Phase III IRIDIUM Study of Inhaled Combination QVM149 in Patients with Uncontrolled Asthma
Basel, September 30, 2019 – Novartis today announced that investigational, once-daily, inhaled QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF) was superior to QMF149 (indacaterol acetate and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 30, 2019 Category: Pharmaceuticals Source Type: clinical trials
Potential for Cortisol Suppression With the Use of High Volume Nasal Mometasone Irrigations in Varying Dosages.
Condition: Chronic Rhinosinusitis (Diagnosis) Intervention: Drug: Nasal Mometasone Rinse Sponsors: Rush University Medical Center; Advanced Rx Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials
